Drug intelligence / Profile preview

filgrastim + trastuzumab + vinorelbine

Development stage: Unknown
Lead developer: SWOG Cancer Research Network
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous, Intravenous

Overview

A combination chemotherapy regimen consisting of filgrastim (G-CSF), trastuzumab, and vinorelbine. This regimen is primarily used for HER2-positive metastatic breast cancer. Trastuzumab targets HER2-overexpressing cancer cells, vinorelbine prevents cancer cell division by inhibiting microtubules, and filgrastim supports immune system recovery by stimulating white blood cell production, allowing for higher chemotherapy dose intensity.

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on filgrastim + trastuzumab + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on filgrastim + trastuzumab + vinorelbine.

Explore the full profile